Cancer cachexia and anabolic interventions: A case report

Journal of Cachexia, Sarcopenia and Muscle

Volumn 3, Issue 4, 2012, Pages 253-263

  Dillon, Edgar L ^a   Basra, Gurjot ^a   Horstman, Astrid M ^a   Casperson, Shanon L ^a   Randolph, Kathleen M ^a   Durham, William J ^a   Urban, Randall J ^a   Diaz Arrastia, Concepcion ^b   Levine, Lyuba ^b   Hatch, Sandra S ^b   Willis, Maurice ^a   Richardson, Gwyn ^b   Sheffield Moore, Melinda ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Amino acids; Cervical cancer; Fatigue; Lean body mass; Quality of life; Testosterone

Indexed keywords

CISPLATIN; MILK PROTEIN; TESTOSTERONE ENANTATE; TOPOTECAN; TUMOR MARKER;

ADULT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CACHEXIA; CANCER CHEMOTHERAPY; CASE REPORT; DIET SUPPLEMENTATION; ENERGY EXPENDITURE; FAT MASS; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LEAN BODY WEIGHT; MUSCLE STRENGTH; PATIENT COMPLIANCE; PHYSICAL CAPACITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; QUALITY OF LIFE; RECURRENT CANCER; SINGLE BLIND PROCEDURE; SKELETAL MUSCLE; UTERINE CERVIX CANCER;

EID: 84880638546     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-012-0066-6     Document Type: Article

References (60)

1. Fearon KC. The Sir David Cuthbertson Medal Lecture 1991. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc. 1991;51: 251-65.
2. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer. 2006;42: 31-41.
3. Argiles JM, Busquets S, Lopez-Soriano FJ. The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol. 2005;37: 1609-19.
4. Gordon JN, Green SR, Goggin PM. Cancer cachexia. QJM. 2005;98: 779-88.
5. Argiles JM. Cancer-associated malnutrition. Eur J Oncol Nurs. 2005;9: S39-50.
6. Argiles JM, Busquets S, Garcia-Martinez C, Lopez-Soriano FJ. Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition. 2005;21: 977-85.
7. Argiles JM, Busquets S, Felipe A, Lopez-Soriano FJ. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol. 2005;37: 1084-104.
8. Chamberlain JS. Cachexia in cancer-zeroing in on myosin. N Engl J Med. 2004;351: 2124-5.
9. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005;8: 265-9.
10. DeJong CH, Busquets S, Moses AG, Schrauwen P, Ross JA, Argiles JM, Fearon KC. Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol Rep. 2005;14: 257-63.
11. Martignoni ME, Kunze P, Hildebrandt W, Kunzli B, Berberat P, Giese T, Kloters O, Hammer J, Buchler MW, Giese NA, Friess H. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res. 2005;11: 5802-8.
12. Tisdale MJ. Molecular pathways leading to cancer cachexia. Physiology (Bethesda). 2005;20: 340-8.
13. Tisdale MJ. Wasting in cancer. J Nutr. 1999;129: 243S-6.
14. Emery PW, Edwards RH, Rennie MJ, Souhami RL, Halliday D. Protein synthesis in muscle measured in vivo in cachectic patients with cancer. Br Med J (Clin Res Ed). 1984;289: 584-6.
15. Dillon EL, Volpi E, Wolfe RR, Sinha S, Sanford AP, Arrastia CD, Urban RJ, Casperson SL, Paddon-Jones D, Sheffield-Moore M. Amino acid metabolism and inflammatory burden in ovarian cancer patients undergoing intense oncological therapy. Clin Nutr. 2007;26: 736-43.
16. Cangiano C, Laviano A, Meguid MM, Mulieri M, Conversano L, Preziosa I, Rossi-Fanelli F. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst. 1996;88: 550-2.
17. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282: E601-7.
18. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab. 2002;87: 1550-4.
19. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89: 3313-8.
20. Yesilova Z, Ozata M, Kocar IH, Turan M, Pekel A, Sengul A, Ozdemir IC. The effects of gonadotropin treatment on the immunological features of male patients with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2000;85: 66-70.
21. Liva SM, Voskuhl RR. Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J Immunol. 2001;167: 2060-7.
22. Bebo Jr BF, Schuster JC, Vandenbark AA, Offner H. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J Immunol. 1999;162: 35-40.
23. Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, Ringel MD, Skipworth RJ, Fearon KC, Hollingsworth MA, Muscarella P, Burghes AH, Rafael-Fortney JA, Guttridge DC. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. 2005;8: 421-32.
24. Chlebowski RT, Herrold J, Ali I, Oktay E, Chlebowski JS, Ponce AT, Heber D, Block JB. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer. 1986;58: 183-6.
25. Lambert CP, Sullivan DH, Evans WJ. Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2003;58: 165-70.
26. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5: 649-55.
27. Kim J, Wang Z, Heymsfield SB, Baumgartner RN, Gallagher D. Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. Am J Clin Nutr. 2002;76: 378-83.
28. Zhang XJ, Chinkes DL, Wolfe RR. Measurement of muscle protein fractional synthesis and breakdown rates from a pulse tracer injection. Am J Physiol Endocrinol Metab. 2002;283: E753-64.
29. Rennie MJ, Bohe J, Smith K, Wackerhage H, Greenhaff P. Branched-chain amino acids as fuels and anabolic signals in human muscle. J Nutr. 2006;136: 264S-8.
30. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda). 2008;23: 160-70.
31. Costelli P, Muscaritoli M, Bonetto A, Penna F, Reffo P, Bossola M, Bonelli G, Doglietto GB, Baccino FM, Rossi Fanelli F. Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest. 2008;38: 531-8.
32. Crouter SE, Clowers KG, Bassett Jr DR. A novel method for using accelerometer data to predict energy expenditure. J Appl Physiol. 2006;100: 1324-31.
33. Pober DM, Staudenmayer J, Raphael C, Freedson PS. Development of novel techniques to classify physical activity mode using accelerometers. Med Sci Sports Exerc. 2006;38: 1626-34.
34. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol. 1983;55: 628-34.
35. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11: 570-9.
36. Jenkinson C, Wright L, Coulter A. Criterion validity and reliability of the SF-36 in a population sample. Qual Life Res. 1994;3: 7-12.
37. Curran SL, Andrykowski MA, Studts JL. Short form of the profile of mood states: psychometric information. Psychol Assess. 1995;7: 80-3.
38. Bratland-Sanda S, Sundgot-Borgen J, Ro O, Rosenvinge JH, Hoffart A, Martinsen EW. "I'm not physically active-I only go for walks": physical activity in patients with longstanding eating disorders. Int J Eat Disord. 2010;43: 88-92.
39. Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz HJ, Nortier JW. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol. 2003;21: 366-73.
40. Noble M, Russell C, Kraemer L, Sharratt M. UW WELL-FIT: the impact of supervised exercise programs on physical capacity and quality of life in individuals receiving treatment for cancer. Support Care Cancer. 2011;20: 865-73.
41. Ohnishi N, Kataoka T, Okamura H. Relationships between roles and mental states and role functional QOL in breast cancer outpatients. Jpn J Clin Oncol. 2011;41: 1112-8.
42. Prue G, Rankin J, Cramp F, Allen J, Gracey J. Fatigue in gynaecological cancer patients: a pilot study. Support Care Cancer. 2006;14: 78-83.
43. Altuwaijri S, Lin HK, Chuang KH, Lin WJ, Yeh S, Hanchett LA, Rahman MM, Kang HY, Tsai MY, Zhang Y, Yang L, Chang C. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Res. 2003;63: 7106-12.
44. Lessard L, Saad F, Le Page C, Diallo JS, Peant B, Delvoye N, Mes-Masson AM. NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. Cell Signal. 2007;19: 1093-100.
45. Keller ET, Chang C, Ershler WB. Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem. 1996;271: 26267-75.
46. Bakkar N, Guttridge DC. NF-kappaB signaling: a tale of two pathways in skeletal myogenesis. Physiol Rev 2010;90: 495-511.
47. Wyke SM, Tisdale MJ. NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br J Cancer. 2005;92: 711-21.
48. Ladner KJ, Caligiuri MA, Guttridge DC. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem. 2003;278: 2294-303.
49. Burckart K, Beca S, Urban RJ, Sheffield-Moore M. Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies. Curr Opin Clin Nutr Metab Care. 2010;13: 410-6.
50. Saini A, Faulkner S, Al-Shanti N, Stewart C. Powerful signals for weak muscles. Ageing Res Rev. 2009;8: 251-67.
51. Zhang P, Chen X, Fan M. Signaling mechanisms involved in disuse muscle atrophy. Med Hypotheses. 2007;69: 310-21.
52. Bakkar N, Guttridge DC. NF-kappaB signaling: a tale of two pathways in skeletal myogenesis. Physiol Rev. 2010;90: 495-511.
53. Baeza-Raja B, Munoz-Canoves P. p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol Biol Cell. 2004;15: 2013-26.
54. Nielsen AR, Pedersen BK. The biological roles of exercise-induced cytokines: IL-6, IL-8, and IL-15. Appl Physiol Nutr Metab. 2007;32: 833-9.
55. Iwase S, Murakami T, Saito Y, Nakagawa K. Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur Cytokine Netw. 2004;15: 312-6.
56. Yang YC, Wang KL, Su TH, Liao HF, Wu MH, Chen TC, Huang MC, Chen YJ. Concurrent cisplatin-based chemoradiation for cervical carcinoma: tumor response, toxicity, and serum cytokine profiles. Cancer Invest. 2006;24: 390-5.
57. Helaly GF, Hussein NG, Refai W, Ibrahim M. Relation of serum insulin-like growth factor-1 (IGF-1) levels with hepatitis C virus infection and insulin resistance. Transl Res. 2011;158: 155-62.
58. Noel JC, Bucella D, Fayt I, Simonart T, Buxant F, Anaf V, Simon P. Androgen receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Int J Gynecol Pathol. 2008;27: 437-41.
59. Long 3rd HJ, Bundy BN, Grendys Jr EC, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23: 4626-33.
60. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachex Sarcopenia Muscle. 2010;1: 7-8.